Clinical Value of miR-3151 Overexpression in Synergistic Interaction with BAALC Host Gene in Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
| Autor: | AI Churkina, NN Mamaev, BV Afanas’ev, L.S. Zubarovskaya, L’va Tolstogo str., Saint Petersburg, Russian Federation, Ildar M. Barkhatov, AI Shakirova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2019 |
| Předmět: |
mir-3151
business.industry medicine.medical_treatment Myeloid leukemia Host gene Hematology Hematopoietic stem cell transplantation acute myeloid leukemia lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lcsh:RC254-282 baalc Oncology hemic and lymphatic diseases Cancer research Clinical value Medicine In patient prognosis allogeneic hematopoietic stem cell transplantation business BAALC |
| Zdroj: | Kliničeskaâ onkogematologiâ, Vol 12, Iss 3, Pp 303-308 (2019) |
| ISSN: | 2500-2139 1997-6933 |
| Popis: | Background. Among a multitude of molecular genetic changes underlying acute myeloid leukemia (AML) disordered epigenetic regulation is of special importance. It includes expression change in miR-3151 gene forming a part of BAALC gene on chromosome 8 in q22.3 locus. At present BAALC gene overexpression is observed in a half of AML patients. A considerable part of them shows a combination of it with an increased transcriptional activity of miR-3151 gene, which is associated with the poorest AML prognosis. Aim. To assess the prognostic value of miR-3151 overexpression in synergistic interaction with BAALC host gene in AML patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Materials & Methods. The trial included bone marrow samples taken from 10 healthy SCT donors and 29 AML patients after receiving allo-HSCT. Relative miR-3151 expression level and relative BAALC copy number were measured by quantitative real-time polymerase chain reaction. Results. The analysis yielded a poor correlation between miR-3151 expression level and blast cell count in bone marrow (r = 0.330; p = 0.005) as well as between the expression levels of miR-3151 and BAALC (r = 0.273; p = 0.020). In addition, a great prognostic value of miR-3151 overexpression in post-transplantation period was confirmed (p = 0.005). Patients with miR-3151 and BAALC co-expression in posttransplantation period have also the poorest prognosis than the control group with regard to both disease-free survival and relapse risks within 2 years after allo-HSCT. Conclusion. Monitoring expression level of miR-3151 and its host gene BAALC in AML patients after receiving allo-HSCT seems to be important not only in AML prognosis but also in therapy efficacy evaluation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|